洞察市场格局
解锁药品研发情报

免费客服电话

18983288589

试用企业版

【ChiCTR2100049535】Social media-delivered care for improving hypertension management in the Tibetan plateau: the WECARE randomised controlled trial protocol

查看原文

立即下载

基本信息

登记号

ChiCTR2100049535

试验状态

尚未开始

药物名称

药物类型

规范名称

首次公示信息日的期

2021-08-02

临床申请受理号

靶点

适应症

Hypertension

试验通俗题目

Social media-delivered care for improving hypertension management in the Tibetan plateau: the WECARE randomised controlled trial protocol

试验专业题目

Social media-delivered care for improving hypertension management in the Tibetan plateau: the WECARE randomised controlled trial protocol

申办单位信息

申请人联系人

申请人名称

联系人邮箱

联系人邮编

6149

联系人通讯地址

临床试验信息

试验目的

The aim of this study is to evaluate the effectiveness of a social media-delivered comprehensive hypertension management programme in patients with uncontrolled hypertension.

试验分类

试验类型

随机平行对照

试验分期

其它

随机化

Following the provision of written informed consent, participants will be randomised in a 1:1 fashion to the WECARE group, or a usual care group, using central randomisation, with variable block size and stratification by gender, age and baseline treatment status (no medication/medical therapy).

盲法

To maintain blinding of study personnel involved in follow-up assessments to group allocation, participants will be informed of their allocation via a WeChat message sent after leaving the trial sites.

试验项目经费来源

China Medical Board

试验范围

目标入组人数

230

实际入组人数

第一例入组时间

2021-06-01

试验终止时间

2024-05-31

是否属于一致性

入选标准

Individuals will be eligible if they are WeChat users, have an operating smartphone, and are aged between 18 or over. Have had a medical history of hypertension documented for six or more months and have at least two measures in the last three months indicating poor control. Participants will be also required to have sufficient Chinese or Tibetan language proficiency, as well as digital literacy in using WeChat and the internet, to enable WeChat-based health education and communication with the WECARE team.；

排除标准

Individuals will be excluded if they are currently receiving any mHealth-based hypertension management programme, have no internet access at their place of residence, or are unable to operate a smartphone, or Bluetooth-enabled BP monitor for the purpose of the trial (e.g., vision, hearing, cognitive or dexterity impairment). Other exclusion criteria include the following: a known cause of secondary hypertension; acute coronary syndrome, coronary revascularisation or stroke, within the past three months; heart failure; or receiving haemodialysis or chemotherapy.；

研究者信息

研究负责人姓名

试验机构

China Medical Board

研究负责人电话

研究负责人邮箱

研究负责人邮编

6150

联系人通讯地址

<END>